Statin Counselling and QRISK Assessment

Clinical Scenario

David Fletcher, 67, books a video consultation to discuss blood test results. His recent bloods show: total cholesterol 6.8, LDL 4.5, HDL 2.3, triglycerides 3.0 mmol/L. His HbA1c has improved from 44 to 39 (no longer pre-diabetic — he has lost 3kg and is more active). His QRISK3 score is 14% (10-year cardiovascular risk). His father died of a heart attack at 75. David has read about statin side effects in the Daily Mail and is sceptical about taking them.

What This Case Tests

Interpreting a lipid profile and explaining it in plain language; explaining QRISK3 and what a 14% 10-year risk means; counselling on statin therapy including addressing media-driven side effect concerns; celebrating the lifestyle achievement (HbA1c improvement) while discussing the need for medication; shared decision-making around statin initiation.

Common Mistakes Trainees Make

The three most common mistakes are: not celebrating the HbA1c improvement before discussing the cholesterol (David has made significant lifestyle changes and deserves recognition), dismissing his statin concerns as media misinformation rather than addressing them with evidence (the nocebo effect from negative statin media coverage is well documented), and not explaining QRISK in accessible terms (a 14% number means nothing without context).

The Consultation Challenge

Start with the good news. David has reversed his pre-diabetes through lifestyle change — his HbA1c has gone from 44 to 39 and he has lost 3kg. This is a remarkable achievement that most patients do not manage. Celebrate it: "Before we look at the cholesterol, I want to say that your diabetes result is brilliant. You have taken yourself out of the pre-diabetic range through your own effort, and that is genuinely impressive."

Now address the cholesterol. His total cholesterol is 6.8 and LDL is 4.5 — both elevated. His HDL is actually good at 2.3 (protective). His QRISK3 is 14%, which means a 14% chance of having a heart attack or stroke in the next 10 years. NICE recommends offering statin therapy at QRISK3 of 10% or above.

Explain QRISK in accessible terms. "Think of it this way — if there were 100 people with your exact risk profile, about 14 of them would have a heart attack or stroke in the next 10 years. A statin would reduce that to about 9 or 10. So we would be preventing 4 or 5 events in every 100 people treated."

Address the statin scepticism. David has read negative coverage in the Daily Mail. This is common — the nocebo effect (expecting side effects based on negative information) accounts for a significant proportion of reported statin side effects. Address it with evidence, not dismissal.

The evidence: muscle symptoms are reported by approximately 10-20% of patients on statins, but in blinded trials where patients do not know whether they are taking statin or placebo, the muscle symptom rate is identical in both groups. This strongly suggests that most muscle symptoms attributed to statins are not caused by them. Genuine statin myopathy (with elevated CK) affects approximately 1 in 10,000 patients.

However, validate his concern rather than dismissing it: "I understand your worry about side effects, and it is good that you have done some research. Let me share what the actual evidence shows, because it is quite different from what the newspapers report."

Present the decision as genuinely shared. "Based on your risk score, I would recommend a statin. But this is your decision. I want to give you all the information and then support whatever you decide."

If he agrees: atorvastatin 20mg is first-line per NICE. Check baseline LFTs (already done), repeat at 3 months, and aim for >40% reduction in non-HDL cholesterol.

Time check: Celebrate the HbA1c improvement in the first 2 minutes. Explain the lipid results and QRISK between minutes 3-6. Address statin concerns between minutes 7-9. Shared decision-making between minutes 10-11. Prescribe and plan follow-up in the final minute.

How Examiners Mark This Case

Data Gathering and Diagnosis: Examiners assess whether you interpret the lipid profile correctly (identifying the elevated LDL as the key modifiable risk factor, noting the protective HDL), explain QRISK3 in meaningful terms, and review the lifestyle changes David has already made. They also look for family history assessment (father died of MI at 75) and screening for other cardiovascular risk factors.

Clinical Management and Medical Complexity: Examiners expect knowledge of the NICE statin threshold (QRISK3 above 10%), the correct first-line statin and dose (atorvastatin 20mg), the monitoring plan (repeat lipids and LFTs at 3 months, aiming for >40% non-HDL cholesterol reduction), and evidence-based responses to statin side effect concerns. Celebrating the pre-diabetes reversal before discussing the cholesterol demonstrates patient-centred care.

Relating to Others: Examiners assess whether you validate David's lifestyle achievement, address his statin concerns with respect rather than dismissal, explain risk in plain language using absolute numbers, and conduct genuine shared decision-making. David should leave feeling informed, respected, and supported in whatever decision he makes.

Example Opening

Strong opening: "Hello David, I have your results here and there is some really good news to start with. Your diabetes marker has gone from pre-diabetic back to completely normal — that is down to the weight you have lost and the exercise you have been doing. That is a fantastic result."

When explaining QRISK: "Now, your cholesterol is higher than we would like, and when I put all your risk factors together — your age, cholesterol, blood pressure, and your father's heart attack — your 10-year risk of a cardiovascular event is about 14%. In plain terms, that means about a 1 in 7 chance over the next 10 years. A statin would roughly halve that additional risk."

When addressing statin concerns: "I know you have read some worrying things about statins, and I take your concerns seriously. But the actual evidence from large studies is quite different from what the papers report. In trials where patients did not know whether they were taking a statin or a sugar pill, the side effects were the same in both groups — which tells us that a lot of what people attribute to statins is actually coincidence."

Avoid: "The Daily Mail is not a medical journal — you should not believe everything you read." (Dismissive and condescending).

How This Appears in the SCA

Statin counselling with media-driven scepticism is a common SCA topic. The examiner assesses whether you can explain cardiovascular risk in accessible terms, address side effect concerns with evidence rather than dismissal, celebrate lifestyle achievements, and support genuine shared decision-making. The consultation should feel like a partnership, not a sales pitch for statins.

Key Statistic

Statin therapy reduces cardiovascular events by approximately 25-35% relative risk. For every 10,000 patients treated with a statin for 5 years, approximately 500 cardiovascular events are prevented while approximately 5 cases of myopathy and 50-100 new cases of diabetes occur. The benefit-to-risk ratio overwhelmingly favours treatment at QRISK3 above 10%.

Relevant Guidelines

• NICE CG181: Cardiovascular disease — risk assessment and reduction
• NICE guideline on lipid modification and statin therapy
• QRISK3 cardiovascular risk calculator.

Frequently Asked Questions

How do I explain QRISK3 in plain language?

Use the "100 people" analogy: "If we took 100 people exactly like you — same age, same blood pressure, same cholesterol, same family history — about 14 of them would have a heart attack or stroke in the next 10 years. A statin would prevent about 4-5 of those events." This makes the abstract percentage concrete and allows the patient to visualise the benefit.

How do I address statin side effect concerns driven by media coverage?

Validate the concern, then present the evidence. "I understand your worry, and it is good to question any medication. Here is what the actual research shows..." Reference the blinded trial data: when patients did not know whether they were taking a statin or placebo, reported side effects were identical in both groups. This is the nocebo effect — expecting side effects makes you notice symptoms you would otherwise ignore. Genuine statin myopathy with elevated CK is very rare (approximately 1 in 10,000).

What is the NICE threshold for offering statin therapy?

NICE recommends offering atorvastatin 20mg to patients with a QRISK3 score of 10% or above (10-year cardiovascular risk). This is a discussion, not an automatic prescription — the patient should understand their risk, the expected benefit, and the potential side effects before deciding. Shared decision-making is explicitly recommended by NICE in this context.

What monitoring is needed after starting a statin?

Check baseline liver function tests (LFTs) before starting. Repeat a full lipid profile and LFTs at 3 months. The target is a greater than 40% reduction in non-HDL cholesterol. If the target is not met, discuss adherence, lifestyle, and consider dose escalation (atorvastatin 40mg or 80mg). If LFTs rise to more than 3 times the upper limit of normal, stop the statin and investigate. Routine CK monitoring is not required unless the patient reports muscle symptoms.

Should I still recommend lifestyle changes if prescribing a statin?

Yes — emphatically. Statins are additive to lifestyle changes, not a replacement. David has already demonstrated the power of lifestyle modification by reversing his pre-diabetes. Reinforce dietary changes (reduce saturated fat, increase fibre, omega-3 fatty acids), physical activity (150 minutes moderate per week), smoking cessation if applicable, and alcohol moderation. Framing the statin as an addition to his successful lifestyle changes — not a failure of them — is important for motivation.